• Reinstatement to ASX quotation on 19 December 2025
• Record quarterly receipts of $2.891 million, up 96% YOY
• Full year receipts of $9.175 million, up 71% on the prior year

Epsilon Healthcare Limited (ASX: EPN) reported a record quarterly performance for the period ending 31 December 2025, reflecting the company's continued recovery and strategic and operational progress. The company recorded its highest-ever customer receipts of $2.891 million for the October-December period, a 96% increase compared to the December 2024 quarter. For the 12 months to 31 December 2025, consolidated receipts were $9.175 million, up 71% on the prior year. The company's revenue run-rate is now above $1 million per month and continues to build. The December quarter also included the receipt of the FY24 R&D tax incentive of $299K, supporting ongoing investment in novel product development, diversification and process improvements. Epsilon's onshore contract development and manufacturing subsidiary delivered substantial growth during the period, underpinned by successful new client acquisitions, the rollout of expanded product and service offerings, and a strong and growing pipeline of new contract opportunities. The Clinics division continued to deliver a strong and consistent performance, maintaining high levels of patient engagement and generating stable, recurring earnings. Epsilon Pharmacy, launched in late February 2025, has rapidly scaled its operations, enhancing patient access to medicines and delivering health outcomes through a strong and disciplined focus on the Quality Use of Medicines (QUM). The company remains focused on optimising its capital structure and maintaining sufficient liquidity headroom as revenues continue to scale.

Consistently exceeding $1 million in monthly revenue, supported by growing revenues and diversified income streams across subsidiary operations including, manufacturing, clinics, and pharmacy. Increasing operating leverage driven by higher manufacturing volumes, disciplined cost management, and scalable integrated healthcare operations.

Epsilon is well positioned to capitalise on the strong operational momentum, with record revenues and growing engagement across its integrated healthcare businesses. The company's contract development and manufacturing operations continue to expand, supported by a robust pipeline of domestic and international opportunities. Epsilon Clinics and Epsilon Pharmacy remain central to the company's patient-focused approach, with the planned opening of a new high street retail pharmacy in Q1 2026 reinforcing accessibility, service quality, and strategic diversification.